Recent advances and new opportunities for targeting human dendritic cells in situ

Abstract

Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-targeting via nanoparticles suggest that combinatorial targeting of multiple human DC subsets may further improve the efficacy of DC targeting.